She is a Professor at the National Taiwan University School of Pharmacy with a distinguished career in immunology, drug discovery, and vaccine adjuvant development.
Her research focuses on small-molecule immune activators widely used as vaccine adjuvants, with significant contributions to understanding and modulating immune responses.
Over more than 20 years of research, she identified key gaps in vaccine adjuvant development, particularly regarding supply, safety, and sustainability issues associated with natural saponin-based technologies derived from Quillaja saponaria.
Her pioneering work has contributed to the development of safer and more consistent adjuvants, overcoming long-standing limitations in toxicity and supply chain reliability.
She is the founder of ImmunAdd, a company focused on next-generation synthetic saponin adjuvants, including IA-05, which offers enhanced immunological performance and improved sustainability compared to traditional sources.
ImmunAdd develops technologies for vaccines targeting tuberculosis, malaria, HIV, shingles, and Epstein–Barr virus (EBV), with a strong focus on expanding global access to advanced immunological tools.
Her work bridges academic research, technological innovation, and global health impact.
She currently serves as Professor at the National Taiwan University School of Pharmacy and Founder of ImmunAdd.
